ATE109662T1 - Matrize mit immunomodulierender wirkung. - Google Patents

Matrize mit immunomodulierender wirkung.

Info

Publication number
ATE109662T1
ATE109662T1 AT89911115T AT89911115T ATE109662T1 AT E109662 T1 ATE109662 T1 AT E109662T1 AT 89911115 T AT89911115 T AT 89911115T AT 89911115 T AT89911115 T AT 89911115T AT E109662 T1 ATE109662 T1 AT E109662T1
Authority
AT
Austria
Prior art keywords
pct
matrix
adjuvants
date
saponins
Prior art date
Application number
AT89911115T
Other languages
English (en)
Inventor
Bror Morein
Karin Lovgren
Kristian Dalsgaard
Jan Thurin
Bo Sundquist
Original Assignee
Bror Morein
Karin Lovgren
Kristian Dalsgaard
Jan Thurin
Bo Sundquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE8901027A external-priority patent/SE8901027D0/xx
Priority claimed from SE8902780A external-priority patent/SE8902780D0/xx
Application filed by Bror Morein, Karin Lovgren, Kristian Dalsgaard, Jan Thurin, Bo Sundquist filed Critical Bror Morein
Application granted granted Critical
Publication of ATE109662T1 publication Critical patent/ATE109662T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT89911115T 1988-09-30 1989-09-28 Matrize mit immunomodulierender wirkung. ATE109662T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25157688A 1988-09-30 1988-09-30
SE8901027A SE8901027D0 (sv) 1989-03-22 1989-03-22 Triterpenoider
SE8902780A SE8902780D0 (sv) 1989-08-16 1989-08-16 Corncerning qa-matrix

Publications (1)

Publication Number Publication Date
ATE109662T1 true ATE109662T1 (de) 1994-08-15

Family

ID=27355484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89911115T ATE109662T1 (de) 1988-09-30 1989-09-28 Matrize mit immunomodulierender wirkung.

Country Status (15)

Country Link
US (1) US5679354A (de)
EP (1) EP0436620B1 (de)
JP (1) JP2501650B2 (de)
AT (1) ATE109662T1 (de)
AU (1) AU632067B2 (de)
CA (1) CA1338888C (de)
DE (1) DE68917474T2 (de)
DK (1) DK175470B1 (de)
ES (1) ES2029758A6 (de)
FI (1) FI911537A0 (de)
HU (1) HUT56722A (de)
IE (1) IE65428B1 (de)
NZ (1) NZ230747A (de)
PT (1) PT91856B (de)
WO (1) WO1990003184A1 (de)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291228B1 (en) 1988-08-03 2001-09-18 Vericore Limited Vaccine
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
DE69432665T3 (de) * 1993-03-29 2007-12-06 Pfizer Inc. Multikomponentenimpfstoff aus clostridien, der saponin als adjuvans benutzt
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
AU1077795A (en) * 1993-09-30 1995-04-18 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
CN1165628A (zh) * 1996-02-14 1997-11-26 浙江农业大学 茶油饼中提取三萜类皂素作为添加剂的应用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
CA2290646C (en) * 1997-05-20 2008-03-11 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
FR2781055B1 (fr) * 1998-07-09 2000-10-13 Immunotech Sa Reactif et methode pour la permeabilisation et l'identification des erythrocytes
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
BR0014281A (pt) * 1999-09-24 2002-05-21 Smithkline Beecham Biolog Vacina contra vìrus de gripe intranasal
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
EP1395605B8 (de) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymere immunoglobulin-fusionsproteine, die auf fc-gamma-rezeptoren mit geringer affinität zielen
US8163289B2 (en) * 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
JP2004528321A (ja) 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ ステロールおよびサポニンを含むポリヌクレオチド結合複合体
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
WO2004052293A2 (en) * 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
WO2004060059A2 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
CA2508281C (en) * 2002-12-23 2011-08-09 Vical Incorporated Method for producing sterile polynucleotide based medicaments
ES2303046T3 (es) * 2003-01-29 2008-08-01 Pfizer Products Inc. Vacunas caninas contra bordetella bronchiseptica.
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
KR20090051129A (ko) * 2004-04-05 2009-05-20 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
DK1838341T3 (da) * 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
ES2325243B1 (es) 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
DK2310046T3 (da) * 2008-06-27 2016-04-25 Zoetis Services Llc Hidtil ukendte adjuvanssammensætninger
EP2376108B1 (de) 2008-12-09 2017-02-22 Pfizer Vaccines LLC Ige ch3 peptidimpstoff
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
PE20120817A1 (es) 2009-07-30 2012-07-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos
PE20161560A1 (es) 2009-09-03 2017-01-11 Pfizer Vaccines Llc Vacuna de pcsk9
EP2490716A1 (de) 2009-10-22 2012-08-29 Universität Leipzig Nachweis eines circovirus bei kälbern mit boviner neonataler pancytopenie
EP3257525A3 (de) 2009-12-22 2018-02-28 Celldex Therapeutics, Inc. Impstoffe zusammensetzungen
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
JP6133207B2 (ja) 2010-07-23 2017-05-24 イスコノバ アーベー インフルエンザワクチン
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
CA2836098C (en) 2011-05-13 2022-06-21 Zoetis Llc Hendra and nipah virus g glycoprotein immunogenic compositions
EP2748194A4 (de) 2011-08-22 2015-01-28 Cangene Corp Clostridium difficile-antikörper
PL2750683T3 (pl) * 2011-10-03 2018-10-31 Mx Adjuvac Ab Nanocząsteczki, sposób ich otrzymywania i ich zastosowanie jako nośnik dla związków amfipatycznych cząsteczek hydrofobowych w dziedzinach medycyny włączając leczenie raka i związki powiązane z żywnością
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
EP4218808A3 (de) * 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvans- und impfstoffzusammensetzungen
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2659906A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659907A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
EP2659908A1 (de) 2012-05-01 2013-11-06 Affiris AG Zusammensetzungen
US8916173B2 (en) 2013-03-08 2014-12-23 Crucell Holland B.V. Acellular pertussis vaccine
WO2014163558A1 (en) * 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
JP6643981B2 (ja) 2013-05-30 2020-02-12 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
WO2014202570A1 (en) 2013-06-17 2014-12-24 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
WO2015000832A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
CN105764921B (zh) 2013-09-17 2020-06-30 台湾浩鼎生技股份有限公司 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途
EP3046580A2 (de) 2013-09-19 2016-07-27 Zoetis Services LLC Adjuvanzien auf ölbasis
JP2017501162A (ja) 2013-12-16 2017-01-12 ゾエティス・サービシーズ・エルエルシー ヘンドラ及びニパウイルスｇ糖タンパク質免疫原性組成物
EP3096785B1 (de) 2014-01-21 2020-09-09 Pfizer Inc Immunogene zusammensetzungen mit konjugierten kapselsaccharid-antigenen und verwendungen davon
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
SG10201806481XA (en) 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
CA3104268A1 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
US10179821B2 (en) 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
WO2016005480A1 (en) 2014-07-10 2016-01-14 Crucell Holland B.V. Influenza virus vaccines and uses thereof
CA2963437A1 (en) 2014-10-15 2016-04-21 Xenothera Composition with reduced immunogenicity
RS58080B1 (sr) 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
DK3244917T5 (da) 2015-01-15 2024-10-14 Pfizer Inc Immunogene sammensætninger til anvendelse i pneumokokvacciner
PT3244920T (pt) 2015-01-16 2023-07-28 Zoetis Services Llc Vacina contra a febre aftosa
CN107466324B (zh) 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
EP3319988A1 (de) 2015-07-07 2018-05-16 Affiris AG Impfstoffe zur behandlung und prävention von ige-vermittelten krankheiten
PE20180657A1 (es) 2015-07-21 2018-04-17 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
BR112018003019A2 (pt) 2015-08-20 2018-09-25 Janssen Vaccines & Prevention Bv vacinas terapêuticas contra hpv18
CA2997181A1 (en) 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
CN114796474A (zh) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
EP3344806A4 (de) 2015-09-04 2019-03-20 OBI Pharma, Inc. Glycanarrays und verfahren zur verwendung
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017172990A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102506895B1 (ko) 2016-04-05 2023-03-08 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
EP3490592A4 (de) 2016-07-27 2020-03-25 OBI Pharma, Inc. Immunogene/therapeutische glycanzusammensetzungen und verwendungen davon
TWI786054B (zh) 2016-07-29 2022-12-11 台灣浩鼎生技股份有限公司 人類抗體、醫藥組合物、及其方法
TWI767959B (zh) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
IL294797B2 (en) 2018-01-23 2024-06-01 Janssen Vaccines Prevention B V Influenza virus vaccines and their uses
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
SG11202009206QA (en) 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
EP3796942A1 (de) 2018-05-23 2021-03-31 ADC Therapeutics SA Molekulares adjuvans
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20210091749A (ko) 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220204567A1 (en) 2019-04-25 2022-06-30 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
MX2021013947A (es) 2019-05-15 2021-12-14 Janssen Vaccines & Prevention Bv Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
EP3969044A1 (de) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Gleichzeitige verabreichung eines saisonalen grippeimpfstoffs und eines adenovirus-basierten impfstoffs gegen das respiratorische synzytialvirus
EP4025247A1 (de) 2019-09-05 2022-07-13 Janssen Vaccines & Prevention B.V. Influenzavirusimpfstoffe und verwendungen davon
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
EP4107170A2 (de) 2020-02-23 2022-12-28 Pfizer Inc. <smallcaps/>? ? escherichia coli ? ? ? -zusammensetzungen und verfahren dafür
WO2021229450A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
MX2022014162A (es) 2020-05-11 2023-02-23 Janssen Pharmaceuticals Inc Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
KR20230009489A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나 바이러스 스파이크 단백질을 암호화하는 rna 레플리콘
BR112022026408A2 (pt) 2020-06-29 2023-01-17 Janssen Vaccines & Prevention Bv Combinação vacinal contra infecção pelo vírus sincicial respiratório
AU2021303722A1 (en) 2020-07-06 2022-12-15 Janssen Pharmaceuticals, Inc. Stabilized Corona virus spike protein fusion proteins
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
IL302362A (en) 2020-10-27 2023-06-01 Pfizer ESCHERICHIA COLI preparations and their methods
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
JP2024500935A (ja) 2020-12-23 2024-01-10 ゼノセラ 抗感染受動免疫療法における、抗体依存性マクロファージ炎症誘発性サイトカインの放出を治療及び／又は予防するためのその使用のためのブタポリクローナル抗体組成物
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CA3211034A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
KR20230165275A (ko) 2021-04-01 2023-12-05 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 piv3 f 단백질
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
TW202413424A (zh) 2022-08-01 2024-04-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫調節蛋白及相關方法
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
SE2200142A1 (en) * 2022-12-13 2024-06-14 Savacc Ab Chrisvacc
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024153674A1 (en) 2023-01-18 2024-07-25 Novavax AB Methods of quantifying saponins present in particles comprising saponin and lipid
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1503388A (en) * 1975-07-01 1978-03-08 Inverni Della Beffa Spa Pharmaceutically active complexes and pharmaceutical compositions containing them
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3813570A1 (de) * 1988-04-22 1989-11-09 Fraunhofer Ges Forschung Verfahren zum fuegen von werkstuecken aus aufschmelzbarem werkstoff mit laserstrahlung

Also Published As

Publication number Publication date
AU4337489A (en) 1990-04-18
WO1990003184A1 (en) 1990-04-05
PT91856B (pt) 1995-07-03
DK175470B1 (da) 2004-11-01
DK55891D0 (da) 1991-03-27
EP0436620B1 (de) 1994-08-10
HU895758D0 (en) 1991-08-28
DE68917474D1 (de) 1994-09-15
HUT56722A (en) 1991-10-28
IE893066L (en) 1990-03-30
AU632067B2 (en) 1992-12-17
DE68917474T2 (de) 1995-03-16
FI911537A0 (fi) 1991-03-28
DK55891A (da) 1991-05-29
CA1338888C (en) 1997-02-04
IE65428B1 (en) 1995-11-01
JP2501650B2 (ja) 1996-05-29
JPH04501714A (ja) 1992-03-26
US5679354A (en) 1997-10-21
NZ230747A (en) 1992-05-26
ES2029758A6 (es) 1992-09-01
EP0436620A1 (de) 1991-07-17
PT91856A (pt) 1990-03-30

Similar Documents

Publication Publication Date Title
DE68917474D1 (de) Matrize mit immunomodulierender wirkung.
DE69939706D1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
CA2302554A1 (en) Oil in water emulsions containing saponins
DK40484D0 (da) Polysaccharid/protein-konjugat,fremgangsmaade til fremstilling deraf og dets anvendelse i en vaccine
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
ATE121947T1 (de) Verbessertes meningokokkale polysaccharidkonjugatvakzin.
ID28003A (id) Turunan-turunan adamantana
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
JPS5231839A (en) Drug for cosmetics and permanent wave in combination
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
DE69206976D1 (de) Verfahren zur inaktivierung von umhüllten viren und sperma
ATE249841T1 (de) Immunogene zubereitungen
FI925649A0 (fi) Karboxivinylpolymerer med newtonsk viskositet
BR9001974A (pt) Aparelho para pressurizar fluidos de poco de descida no poco,aparelho para assentar um obturador inflavel dentro de um poco subterraneo e processo para ativar um dispositivo de obturador inflavel dentro de um poco subterraneo
AU6462396A (en) Vaccine for infectious agents, composition for treating and preventing hiv infections
NL180008B (nl) Werkwijze voor het bereiden van herbicide preparaten alsmede werkwijze voor het bereiden van voor toepassing in dergelijke preparaten geschikte 1,2-dimethyl-3,5-difenylpyrazoliumverbindingen.
IT1178800B (it) Composizioni farmaceutiche e loro uso come midriatici
DK191290A (da) Extracellulaer exopolymer, fremgangsmaade til fremstilling af samme og farmaceutiske praeparater indeholdende exopolymeren
BR9600773A (pt) Benzenossulfonilurélas ou - tiourélas substituídas processo para sua preparação uso e medicamento
NO911049L (no) Matrise med immun-modulerende aktivitet.
DE69721498D1 (de) Immunogener komplex, iscom, zur herstellung eines impfstoffs für jugendliche
BR8902460A (pt) Processo para preparacao de hidrolisado de proteina de baixa imunogenicidade e antigenicidade,para uso enteral
ITMI932171A1 (it) Procedimento per l&#39;estrazione di colori naturali mediante bentonite
RU96107439A (ru) Способ подготовки мягких контактных линз к применению

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time